The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The clinical and physiological spectrum of interferon‐alpha induced thyroiditis: Toward a new classification†
Open accessAbstract
Interferon-alpha (IFNalpha) is a major treatment modality for several malignant and nonmalignant diseases, especially hepatitis C. Prospective studies have shown that up to 15% of patients with hepatitis C receiving IFNalpha develop clinical thyroid disease, and up to 40% were reported to develop thyroid antibodies. Some of these complications may result in discontinuation of interferon therapy. Thus, interferon induced thyroiditis (IIT) is a major clinical problem for patients receiving interferon therapy. IIT can be classified as autoimmune type and non-autoimmune type. Autoimmune IIT may manifest by the development of thyroid antibodies without clinical disease, or by clinical disease which includes both autoimmune hypothyroidism (Hashimoto's thyroiditis) and autoimmune thyrotoxicosis (Graves' disease). Non-autoimmune IIT can manifest as destructive thyroiditis or as hypothyroidism with negative thyroid antibodies. Early detection and therapy of these conditions is important in order to avoid complications of thyroid disease such as cardiac arrhythmias. While it is not clear which factors contribute to the susceptibility to IIT, recent evidence suggests that genetic factors, gender, and hepatitis C virus infection may play a role. In contrast, viral genotype and therapeutic regimen do not influence susceptibility to IIT. The etiology of IIT is unknown and may be secondary to immune modulation by IFNalpha and/or direct effects of interferon on the thyroid. In this review we discuss the clinical and pathophysiological aspects of IIT, and we are proposing a new, etiology-based classification of IIT, as well as an algorithm for diagnosis and treatment of IIT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279
Epidemiology and estimated population burden of selected autoimmune diseases in the United States
Jacobson, D. L., Gange, S. J., Rose, N. R., & Graham, N. M. H. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4412 · Cited by 1,667
Chronic Autoimmune Thyroiditis
Dayan, C. M., & Daniels, G. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350206 · Cited by 904
Interferon-α and Autoimmune Thyroid Disease
Prummel, M. F., & Laurberg, P. (2003) · Thyroid · doi:10.1089/105072503322238809 · Cited by 221
KOH, L. K. H., GREENSPAN, F. S., & YEO, P. P. B. (1997) · Thyroid · doi:10.1089/thy.1997.7.891 · Cited by 185
Cited by
Hashimoto thyroiditis: Clinical and diagnostic criteria
Caturegli, P., De Remigis, A., & Rose, N. R. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.007 · Cited by 1,057
The etiology of autoimmune thyroid disease: A story of genes and environment
Tomer, Y., & Huber, A. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.02.007 · Cited by 351
Self-citationDrugs affecting thyroid function
Barbesino, G. (2010) · Thyroid · doi:10.1089/thy.2010.1635 · Cited by 146
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
Grossmann, M., Premaratne, E., Desai, J., & Davis, I. D. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03253.x · Cited by 109
Metadata
- Authors
- Mandac, J. C., Chaudhry, S., Sherman, K. E., & Tomer, Y.
- Venue
- Hepatology
- Published
- 2006-04
- Volume
- 43
- Issue
- 4
- Pages
- 661-672
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1986032822
- Cited by
- 193
- References
- 5
- FWCI
- 10.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.